{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T09:12:26Z","timestamp":1788772346838,"version":"build-2803163510"},"reference-count":38,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T00:00:00Z","timestamp":1788739200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T00:00:00Z","timestamp":1788739200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/501100000568","name":"British Society for Rheumatology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000568","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["acrjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Arthritis &amp; Rheumatology"],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Nonmelanoma skin cancer (NMSC) is one of the most common malignancies in rheumatoid arthritis (RA). This analysis assessed NMSC risk with JAK inhibitors (JAKi) compared to interleukin\u20106 receptor inhibitors (IL\u20106Ri).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study used data from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis linked to the National Cancer Registration and Analysis Service. People with RA initiating first JAKi or IL\u20106Ri without prior exposure to the comparator class were included. The primary analysis was ever\u2010exposed model with first 90 days after treatment initiation excluded. Cox proportional hazards models estimated hazard ratios (HRs) with inverse probability of treatment weighting (IPTW) to adjust for confounding. Secondary analysis was receiving\u2010treatment analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 3,985 people with RA were included in primary analysis, with 116 first\u2010ever NMSC recorded. The IPTW HR for JAKi versus IL\u20106Ri was 1.64 (95% confidence interval [CI] 0.85\u20133.17). The IPT\u2010weighted absolute rate difference was 3.3 events per 1,000 person\u2010years with JAKi versus IL\u20106Ri, which is around one additional NMSC event for every 307 patients who initiated JAKi rather than IL\u20106Ri and were observed for one year. In receiving\u2010treatment analysis, 32 and 19 NMSC events occurred among patients actively receiving IL\u20106Ri and JAKi, with IPTW HR of 1.82 (95% CI 0.84\u20133.96).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Initiation of JAKi was associated with a clinically small, plausibly higher NMSC risk than IL\u20106Ri, although not statistically significant over 3.3 years. Rheumatologists and patients should weigh the potential risk of NMSC against the benefits of disease control when considering treatment choices.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/art.70272","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T07:59:21Z","timestamp":1783583961000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Nonmelanoma Skin Cancer Risk With\n                    <scp>JAK<\/scp>\n                    Inhibitors Compared to Interleukin\u20106 Receptor Inhibitors in Rheumatoid Arthritis: Results From a National Cohort Study"],"prefix":"10.1002","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9186-1743","authenticated-orcid":false,"given":"Zixing","family":"Tian","sequence":"first","affiliation":[{"name":"Centre for Musculoskeletal Research, Division of Musculoskeletal and Dermatological Sciences, School of Biological Sciences, Faculty of Biology Medicine and Health University of Manchester  Manchester United Kingdom"},{"name":"Manchester Academic Health Science Centre  Manchester United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0377-1575","authenticated-orcid":false,"given":"Lianne","family":"Kearsley\u2010Fleet","sequence":"additional","affiliation":[{"name":"Centre for Musculoskeletal Research, Division of Musculoskeletal and Dermatological Sciences, School of Biological Sciences, Faculty of Biology Medicine and Health University of Manchester  Manchester United Kingdom"},{"name":"Manchester Academic Health Science Centre  Manchester United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sizheng Steven","family":"Zhao","sequence":"additional","affiliation":[{"name":"Centre for Musculoskeletal Research, Division of Musculoskeletal and Dermatological Sciences, School of Biological Sciences, Faculty of Biology Medicine and Health University of Manchester  Manchester United Kingdom"},{"name":"Manchester Academic Health Science Centre  Manchester United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Galloway","sequence":"additional","affiliation":[{"name":"Centre for Rheumatic Diseases King's College London  London United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Lunt","sequence":"additional","affiliation":[{"name":"Centre for Musculoskeletal Research, Division of Musculoskeletal and Dermatological Sciences, School of Biological Sciences, Faculty of Biology Medicine and Health University of Manchester  Manchester United Kingdom"},{"name":"Manchester Academic Health Science Centre  Manchester United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kath","family":"Watson","sequence":"additional","affiliation":[{"name":"Centre for Musculoskeletal Research, Division of Musculoskeletal and Dermatological Sciences, School of Biological Sciences, Faculty of Biology Medicine and Health University of Manchester  Manchester United Kingdom"},{"name":"Manchester Academic Health Science Centre  Manchester United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narges","family":"Azadbakht","sequence":"additional","affiliation":[{"name":"Centre for Musculoskeletal Research, Division of Musculoskeletal and Dermatological Sciences, School of Biological Sciences, Faculty of Biology Medicine and Health University of Manchester  Manchester United Kingdom"},{"name":"Manchester Academic Health Science Centre  Manchester United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"British Society for Rheumatology Biologics Register in Rheumatoid Arthritis Contributors Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8242-9262","authenticated-orcid":false,"given":"Kimme L.","family":"Hyrich","sequence":"additional","affiliation":[{"name":"Centre for Musculoskeletal Research, Division of Musculoskeletal and Dermatological Sciences, School of Biological Sciences, Faculty of Biology Medicine and Health University of Manchester  Manchester United Kingdom"},{"name":"Manchester Academic Health Science Centre  Manchester United Kingdom"},{"name":"Manchester Biomedical Research Centre, National Institute of Health Research Manchester University NHS Foundation Trust  Manchester United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,9,7]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.17873"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.12.066"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-201969"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i262"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-200622"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2109927"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-222543"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-224049"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keac190"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.11.043"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.41095"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2019.03.002"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.5507"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.7326\/ANNALS-24-01871"},{"key":"e_1_2_7_16_1","author":"NRAS and BSRBR\u2010RA research priority survey","year":"2023","journal-title":"British Society for Rheumatology"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209285"},{"key":"e_1_2_7_18_1","article-title":"National Cancer Registration and Analysis Service (NCRAS)","volume":"31","author":"National Disease Registration Service","year":"2025","journal-title":"NHS England. January"},{"key":"e_1_2_7_19_1","volume-title":"Adalimumab, Etanercept, Infliximab, Certolizumab Pegol, Golimumab, Tocilizumab and Abatacept for Rheumatoid Arthritis Not Previously Treated With DMARDs or After Conventional DMARDs Only Have Failed 2016","author":"National Institute for Health and Care Excellence","year":"2016"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/25.2.206"},{"key":"e_1_2_7_21_1","unstructured":"Cancer Registration Statistics England 2022.NHS England; October 17 2024. Updated June 10 2025. Accessed December 10 2024.https:\/\/digital.nhs.uk\/data-and-information\/publications\/statistical\/cancer-registration-statistics\/england-2022"},{"key":"e_1_2_7_22_1","unstructured":"National Disease Registration Service (NDRS).Standard cancer group definitions. NHS England. September 11 2024. Updated August 6 2025. Accessed December 10 2024.https:\/\/digital.nhs.uk\/ndrs\/data\/data-outputs\/cancer-data-hub\/standard-cancer-group-definitions"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01854-3"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223356"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kez320"},{"key":"e_1_2_7_26_1","volume-title":"Practical on Competing Risks in Survival Analysis","author":"Lunt M.","year":"2016"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-022-02108-0"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr2.11232"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223636"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ard.2026.02.015"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaf556"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)61196-X"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.38385"},{"key":"e_1_2_7_34_1","unstructured":"A study of baricitinib in participants with rheumatoid arthritis (RA\u2010BRANCH).ClinicalTrials.gov. September 12 2019. Updated July 17 2025. Accessed September 9 2025.https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT04086745"},{"key":"e_1_2_7_35_1","unstructured":"ClinicalTrials.gov. 2026 A study of baricitinib (LY3009104) in participants with rheumatoid arthritis (RA\u2010BRIDGE)"},{"key":"e_1_2_7_36_1","volume-title":"Diabetes and Cardiovascular Disease","author":"International Diabetes Federation","year":"2016"},{"key":"e_1_2_7_37_1","article-title":"EMA recommends measures to minimise risk of serious side effects with Janus kinase inhibitors for chronic inflammatory disorders","author":"European Medicines Agency's Pharmacovigilance Risk Assessment Committee","year":"2022","journal-title":"European Medicines Agency"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223356"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.01.053"}],"container-title":["Arthritis &amp; Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/art.70272","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/art.70272","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/art.70272","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T09:00:21Z","timestamp":1788771621000},"score":1,"resource":{"primary":{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/10.1002\/art.70272"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,7]]},"references-count":38,"alternative-id":["10.1002\/art.70272"],"URL":"https:\/\/doi.org\/10.1002\/art.70272","archive":["Portico"],"relation":{},"ISSN":["2326-5191","2326-5205"],"issn-type":[{"value":"2326-5191","type":"print"},{"value":"2326-5205","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,7]]},"assertion":[{"value":"2026-03-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-25","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-07","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"art.70272"}}